| Death associated protein kinase (DAPK) |
Mib |
Yeast-two-hybrid |
Ubiquitylation, Proteasomal degradation |
Antagonize the anti-apoptotic function of DAPK |
[23]
|
| Cellular Fas-associated death domain -like IL-1b converting enzyme-like inhibitory protein (cFLIP) |
Mib |
IP |
Caspase-dependent degradation |
Decrease the association of caspase-8 and cFLIP, leading to cell apoptosis |
[24]
|
| Jagged 1a and 1b (Jag1a and 1b) |
Mib |
Yeast-two-hybrid |
Ubiquitylation |
Activate the Notch signaling pathway |
[11]
|
| Jagged 2 (Jag2) |
Mib, Mib2 |
IP, GST pulldown |
Internalization, Ubiquitylation |
Activate the Notch signaling pathway |
[12], [66]
|
| xDelta 1 |
Mib |
IP |
Ubiquitylation, Internalization |
Activate the Notch signaling pathway |
[9]
|
| DeltaA |
Mib |
IP |
Predicted: Ubiquitylation, Internalization |
Activate the Notch signaling pathway |
[10]
|
| DeltaC |
Mib, Mib2 |
IP |
Ubiquitylation, Internalization |
Activate the Notch signaling pathway |
[10]
|
| DeltaD |
Mib |
IP |
Ubiquitylation, Internalization |
Activate the Notch signaling pathway |
[9], [10]
|
| Mind bomb 2 (Mib2) |
Mib |
IP |
Ubiquitylation |
Predicted: Activate the Notch signaling pathway |
[15]
|
| Sorting nexin 5 (Snx5) |
Mib |
Yeast-two-hybrid |
unknown |
Predicted: Mind bomb-mediated endocytosis of Notch ligand proteins |
[64]
|
| TANK-binding kinase 1 (TBK1) |
Mib |
Mass spectrometry |
K63-linked ubiquitylation activation |
Regulate innate immune responses to RNA virus infection |
[62]
|
| Cyclin-dependent kinase 5 (CDK5) |
Mib |
Mass spectrometry |
Localization |
Inhibit neurite outgrowth |
[59]
|
| PAR-1 |
Mib |
Mass spectrometry |
Phosphorylation of Mib, leading to the proteasomal degradation of Mib |
Repress the Notch signaling pathway and stimulate neuronal differentiation |
[68]
|
| Receptor-like tyrosine kinase (RYK) |
Mib |
Mass spectrometry |
Ubiquitylation, Proteasomal degradation, Internalization |
Activate the Wnt signaling pathway |
[25]
|
| Survival of motor neuron protein (SMN) |
Mib |
IP |
Ubiquitylation, Proteasomal degradation |
A therapeutic candidate for the spinal muscular atrophy |
[63]
|
| B-cell CLL/lymphoma 10 (BCL10) |
Mib2 |
Mass spectrometry |
unknown |
Activate the NF-κB signaling pathway |
[67]
|
| Inhibitor of nuclear factor kappa-B kinase subunit gamma (IKKγ) |
Mib2 |
IP |
Ubiquitylation |
Activate the NF-κB signaling pathway |
[67]
|
| Transforming growth factor-β-activated kinase 1 (TAK1) |
Mib2 |
IP |
Activation |
Activate the NF-κB signaling pathway |
[67]
|
|
N-methyl-D-aspartate receptor (NMDAR) |
Mib2 |
Yeast-two-hybrid |
Ubiquitylation |
Reduce the NMDAR activity |
[65]
|
| Ubiquitin specific protease 1 (Usp1) |
Mib, Mib2 |
Yeast-two-hybrid, IP |
unknown |
unknown |
this study |
| Ubiquitin specific protease 9 (Usp9) |
Mib, Mib2 |
Yeast-two-hybrid, IP |
unknown |
unknown |
this study |
| Tumor-necrosis-factor-receptor-associated factor-binding domain (Trabid) |
Mib, Mib2 |
Yeast-two-hybrid, IP |
Ubiquitylation |
unknown |
this study |
| Factor inhibiting HIF 1 (Fih-1) |
Mib, Mib2 |
Yeast-two-hybrid, IP |
Ubiquitylation |
unknown |
this study |
